Cytorex Biosciences, Inc. , a Florida based Biopharma preclinical stage company, names William Jimenez, MBA as CEO, and Carlos M. Garcia, MEIE as CFO.
Online PR News – 29-November-2019 – SUNRISE – Nov. 27, 2019
Cytorex Bioscieneces, Inc., a Florida based Biopharma preclinical stage company, announced today the appointment of Mr. William J. Jimenez, MBA, as the new President & Chief Executive Officer of the Company. Mr. Jimenez substitutes Prof. David J. Martucci, who remains as Chairman and Chief Scientific Officer. The company also announced Mr. Carlos M. Garcia, MEIE, as the new Treasurer and Chief Financial Officer. Mr. Garcia will retain his position as Secretary of the company.
'I am very honored to become the new President and CEO of Cytorex. We are completing all required preclinical work to File with the FDA, an Investigational New Drug (IND) application for Glioblastoma Multiforme, which according with the cancer.gov website is: a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma multiforme, and grade IV astrocytoma", Indicated Jimenez.
"The median survival time for patients with GBM is 15 to 16 months in people who get surgery, chemotherapy, and radiation treatment. Median means half of all patients with this tumor survive to this length of time", concluded Jimenez.
"After serving as Chief Operations Officer of the company, I am ready for this new challenge. Our first and foremost motivation is to help patients with GBM, which unfortunately has a very somber prognosis" said Garcia.
For additional information on our company and technology, you can visit Cytorex"s website at www.cytorex.com.